Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer

Table 3 Univariate and multivariate survival analyses of patients treated with targeted therapy and combined targeted-immunotherapy

Variable	PFS months (95%CI)	Univariate P value	HR	95%CI	Multivariate P value
Age groups (year)		0.819			0.677
> 60	3.7 (3.11-4.29)		1.05	0.68-1.61
≤ 60	4.7 (3.98-5.43)		0.95	0.62-1.46
Gender		0.471			0.623
Female	3.7 (2.85-4.55)		1.17	0.76-1.80
Male	4.2 (2.99-5.41)		0.85	0.56-1.31
Radical surgery		0.591			0.829
Yes	4.3 (3.04-5.56)		0.87	0.52-1.44
No	3.5 (3.13-3.87)		1.15	0.69-1.91
Treatment line		0.254			0.125
Third-line	3.8 (3.01-4.59)		1.40	0.79-2.48
Fourth-line	5.4 (2.75-7.85)		0.72	0.40-1.27
Treatment plan		0.003			0.000
TT	3.4 (2.83-3.97)		2.07	1.28-3.32
TT + ICI	6.0 (4.26-7.75)		0.48	0.30-0.78
Primary site		0.006			0.000
Rectal cancer	4.8 (3.79-5.81)		0.55	0.36-0.84
Colon cancer	3.4 (2.95-3.85)		1.81	1.19-2.75
Metastatic status					0.005
LM	5.0 (4.50-5.51)	0.511	0.82	0.45-1.48
LuM	3.4 (2.07-4.73)	0.825	0.95	0.61-1.49
PM	4.3 (3.01-5.59)	0.999	1.00	0.40-2.47
LM + LuM	3.5 (2.11-4.89)	0.322	1.31	0.77-2.25
LuM + PM	1.3 (0.18-2,42)	0.303	1.84	0.58-5.90
LM + PM	3.7 (2.71-4.69)	0.000	18.67	5.21-66.97
OM	4.0 (3.20-4.80)	0.299	0.75	0.44-1.28
CEA level					0.894
≤ 5	4.7 (2.74-6.66)	0.459	0.81	0.46-1.42
5 < CEA ≤ 25	4.0 (2.65-5.35)	0.828	1.06	0.65-1.72
> 25	3.7 (3.02-4.39)	0.679	1.09	0.71-1.67
Gene mutation status
KRAS mutation	3.5 (2.84-4.16)	0.400	0.80	0.47-1.35	0.216
NRAS mutation	3.2 (1.40-5.00)	0.715	0.84	0.33-2.12	0.835
dMMR	3.3 (2.82-3.78)	0.564	0.66	0.16-2.70	0.394

PFS: Progression-free survival; TT: Targeted therapy; ICI: Immune checkpoint inhibitor; HR: Hazard ratio; 95%CI: 95% confidence interval; LM: Liver metastasis; LuM: Lung metastasis; PM: Peritoneal metastasis; OM: Other metastases; CEA: Carcinoembryonic antigen; dMMR: Deficient mismatch repair.